Medicare is spending far less than expected on new Alzheimer’s drugs

Medicare is spending far less than expected on new Alzheimer’s drugs

People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated. Uptake for the drugs, Leqembi and Kisunla, has been so muted that Medicare is not forecasting significant spending on them in 2026 or 2027, a spokesperson for the Centers for Medicare and Medicaid Services told STAT. It’s a dramatic shift from two years ago, when Medicare projected it would spend billions of dollars a…